BioMarin Pharmaceuticalvs.Vertex Pharmaceuticals
BMRN vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 11× larger than BioMarin Pharmaceutical by market cap; Vertex Pharmaceuticals trades at the lower P/E (27.9 vs 42.6); year to date, Vertex Pharmaceuticals leads (+7.1% vs −0.5%).
Side by side
| BMRN | VRTX | |
|---|---|---|
| Market cap | $11.4B | $121B |
| Price | $59.12 | $485.39 |
| Today | −1.4% | −2.2% |
| Return YTD | −0.5% | +7.1% |
| Return 1Y | +0.5% | +1.2% |
| P/E | 42.6 | 27.9 |
| P/S | 3.5 | 9.9 |
| P/B | 1.8 | 6.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BioMarin PharmaceuticalBMRN
Biopharma specialized in enzyme and gene therapies for rare genetic diseases.
Full BMRN profile →Vertex PharmaceuticalsVRTX
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Full VRTX profile →More comparisons in Biotech & innovation
See where BMRN and VRTX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →